Press Releases AegirBio AB

Equities

AEGIR

SE0014401121

Delayed Nasdaq Stockholm Other stock markets 05:25:26 2024-05-15 EDT			5-day change	1st Jan Change
0.513 ^SEK	-4.11%		+0.19%	-56.07%

04-19	AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract	MT
04-09	AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AegirBio AB calls for payment of Tranche 1 of SEK 7.50 million and intends to carry out a directed set-off issue of 5,175,374 shares to Atlas Special Opportunities, LLC	05-13	AQ
AEGIRBIO Receives Milestone Payment under RadX NIH	05-08	AQ
AEGIRBIO AB ADVANCES FURTHER WITH "ACCESSIBILITY" MILESTONE COMPLETION IN RADx® TECH PROGRAM	04-30	AQ
AegirBio AB's subsidiary initiates arbitration against Salofa Oy	04-18	AQ
AegirBio's chairman has announced his intention to leave the board of directors	04-09	AQ
AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval	04-09	AQ
Aegirbio Expands Oral Health Scientific Advisory Board with Professor Iain L.C. Chapple	02-27	AQ
Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio's Scientific Advisory Board	01-24	AQ
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 5.00	12-20	AQ
AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program	11-01	AQ
AegirBio focuses on RadX project, will not uphold CE-markings for the MagniaReader TDM tests	11-01	AQ
Interview with AegirBio CEO Mr Marco Witteveen	23-10-30	AQ
AegirBio promotes Dr. Vasiliki Fragkou to Chief Operating Officer from November 1, 2023.	23-10-09	AQ
AEGIRBIO RECEIVES $1.2 MILLION NIH AWARD	23-10-06	AQ
AegirBio AB has received National Institutes of Health (NIH) programmatic approval for an accessibility project	23-07-17	AQ
Aegirbio signs agreement with Salofa for the veterinary market and receives a first order worth approximately SEK 2 million.	23-07-07	AQ
AegirBio appoints new CEO	23-05-30	AQ
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 10.00	23-03-23	AQ
The Disciplinary Committee of Nasdaq Stockholm has resolved that AegirBio shall pay fees	23-03-14	AQ
AEGIRBIO PRESENTATION AT ACTRIMS	23-02-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AegirBio AB

Equities

AEGIR

SE0014401121

Press Releases

Filters